Hugues Bienaymé

BioTransplant, Inc. is a life science company. The company discovers, develops and commercializes therapeutics, therapeutic devices and therapeutic regimens designed to suppress undesired immune responses and enhance the body's ability to accept donor cells, tissues and organs. The company was founded on March 20, 1990 and is headquartered in Charlestown, MA.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Part of Sanofi, Imtix is a French company that develops and markets pharmaceuticals for transplantation. The company is based in Lyon, France. The company was founded by Gilles Alberici. Imtix was acquired by SangStat Medical Corp. from Rhone-Poulenc SA on October 01, 1998 for $31 million.

Basf Performance Products Ltd. manufactures chemical products. It offers dyes and pigments, plastics, and other inorganic basic chemicals. The company was founded on September 12, 1996 and is headquartered in Cheadle, the United Kingdom.

Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products.

Founded in 1982, Aventis Pharma SARL is a French pharmaceutical company that manufactures pharmaceuticals. Part of Sanofi, the company is based in Antony, France.

Anceris SA specializes in developing therapeutic products for treatment of cancer. The company was founded in February 2000 and is headquartered in Paris, France.

QuantifiCare SA provides medical image processing tools and services. The company offers its services to pharmaceutical and biotechnology companies, medical device manufacturers, diagnosis and research companies, radiopharmaceutical companies and research institutions. QuantifiCare was founded in February 2001 and is headquartered in Valbonne, France.

Ferring Research Institute, Inc. is a biopharmaceutical company, which engages in identifying, developing, and marketing of products. It focuses on the fields of endocrinology, gastroenterology, infertility, obstetrics, urology and osteoarthritis. The company is headquartered in San Diego, CA.

Octalfa SAS is a family-owned, independent private equity holding and investment company controlled by Gilles Alberici. Octalfa was established in 2006 and is based near Lyon in Eastern France. The firm manages a portfolio of participations in Life Sciences companies. They are also the key investor of Octalfa 360 Health and Green Technologies, a sector mutual fund invested in listed equity, co-managed by 360 Asset Managers SA and Xénia SARL (aka Xénia Gestion Privée). The fund focuses on sectors such as biotechnology and clean technology. Octalfa is committed to public health issues, and established the Dominique Alberici-Octalfa Corporate Foundation to support initiatives aimed at improving medical and paramedical care for cancer patients and the disabled.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France.

Diverchim SA provides pharmaceutical services. It offers computer aided drug, medicinal chemistry, immunochemistry, chemical development, analytical services, and discovery. The firm products are building blocks and screening, collection, and new tools for asymmetric catalysis. The company was founded by Jean Louis Brayer and Benoit Folleas in March 2001 and is headquartered in Roissy-en-France, France.

Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France.

EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France.

Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom.

Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland.

Orega Biotech SAS provides monoclonal antibody-based immunotherapy for cancer patients. It specializes in the discovery of novel targets and the development of first-in-class monoclonal antibodies for the treatment of cancer. The company was founded by Gilles Alberici, Nathalie Bonnefoy, Jean-François Eliaou, and Armand Bensussan in 2010 and is headquartered in Écully, France.

Fonds National de La Recherche is a private company based in Esch-sur-Alzette, Luxembourg. The Luxembourger company engages in research of science and humanities and research funding activities. It was founded in 1999, and Marc Schiltz has been the CEO of the company since 2011.

Mathym SAS engages in the development, manufacture, and commercialization of colloidal solutions for biomedical applications. It specializes in nano-dispersions. The company was founded by Julien Alberici and Frederic Chaput in September 1, 2013 and is headquartered in Champagne-au-Mont-d'Or, France.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Delpharm SAS develops and manufactures drugs. The company is headquartered in Issy-les-Moulineaux, France.

Adienne SA is a biopharmaceutical company engages in the provision of medical development. It focuses on orphan drugs for the treatment of various haematological and immunological diseases. The company was founded on Lugano, Switzerland.

Jazz Pharmaceuticals II SASU engages in the development of biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases. Its lead assets are pegcrisantaspase (Asparec), a PEGylated recombinant L-asparaginase from Erwinia chrysanthemi, and related intellectual property. The company was founded in 2008 and is headquartered in Ecully, France.

Société de Chimie Thérapeutique is a French Medchem Society based in Malabry, France. The society is administered by an Executive Board and provides for the re-election or replacement of its members through a call for nominations process. The society also supports young researchers by providing a prestigious prize entitled “Prix d’Encouragement à la Recherche en Chimie Thérapeutique” sponsored by Institut de Recherche Servier, which is devoted to junior European scientists. The society complies with the law of July 10, 2012, on various provisions relating to electronic communications and transposes the European Directive No. 2009/136/EC of the European Parliament and of the Council of November 25, 2009, regarding the new constraints and obligations of publishers and owners of websites on information. The call for 2023 Young Medicinal Chemist in Industry Award is now closed, and the new call will be announced in November 2023.

Part of Sanofi, Gencell SA is a company based in Vitry-sur-Seine, France. The French company operates a cancer treatment center.

Polyplus-transfection SA develops and sells solutions for the delivery of nucleic acids in research, bio production, and therapeutics. Its products are transfection reagents and trademarks, mainly for gene and cell therapies. The company was founded by Jean-Paul Behr, Anne-Lise Monjanel, Joelle Bloch, and Patrick Metz in January 2001 and is headquartered in Illkirch-Graffenstaden, France.